Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    R-Tofisopam

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: R-tofisopam, Ez15i5d6c1, 82059-50-5, (5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine, (+)-(5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine, Dextofisopam [usan]
    Molecular Formula
    C22H26N2O4
    Molecular Weight
    382.5  g/mol
    InChI Key
    RUJBDQSFYCKFAA-HNNXBMFYSA-N
    FDA UNII
    EZ15I5D6C1
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
    2.1.2 InChI
    InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3/t15-/m0/s1
    2.1.3 InChI Key
    RUJBDQSFYCKFAA-HNNXBMFYSA-N
    2.1.4 Canonical SMILES
    CCC1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C
    2.1.5 Isomeric SMILES
    CC[C@H]1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C
    2.2 Other Identifiers
    2.2.1 UNII
    EZ15I5D6C1
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine

    2. Egyt-341

    3. Grandaxin

    4. Levotofisopam

    5. Tofisopam

    6. Tofizopam

    2.3.2 Depositor-Supplied Synonyms

    1. R-tofisopam

    2. Ez15i5d6c1

    3. 82059-50-5

    4. (5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine

    5. (+)-(5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine

    6. Dextofisopam [usan]

    7. Dextofisopam (usan/inn)

    8. Dextofisopam [usan:inn]

    9. Unii-ez15i5d6c1

    10. Dextofisopam [inn]

    11. Schembl236796

    12. Schembl8086913

    13. Chembl2107331

    14. Dtxsid00231554

    15. Zinc608106

    16. Db06582

    17. D03737

    18. Q27277442

    19. (5r)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine

    20. 5h-2,3-benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-, (5r)-

    21. 5h-2,3-benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl, (5r)

    22. Jpu

    2.4 Create Date
    2005-08-09
    3 Chemical and Physical Properties
    Molecular Weight 382.5 g/mol
    Molecular Formula C22H26N2O4
    XLogP33.2
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count6
    Exact Mass382.18925731 g/mol
    Monoisotopic Mass382.18925731 g/mol
    Topological Polar Surface Area61.6 Ų
    Heavy Atom Count28
    Formal Charge0
    Complexity579
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in irritable bowel syndrome (IBS).

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Antidepressive Agents

    Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)